IDIGH Program/CR-HMR Joint Seminar (June 12, 2019) - Research Institute of the McGill University Health Centre
Newsletter - Banner
Where: At the Research Institute of the McGill University Health Centre (RI‑MUHC), Glen Site, block E, room M1.3509, 1001 Decarie Boulevard, Montreal, Quebec H4A 3J1
When: Wednesday, June 12, 1-2 p.m.
Speaker: Jorge Kalil, MD, PhD, FRPC, Dr.h.c
Distinguished Visiting Professor
Evergrande Center for Immunologic Diseases, Harvard Medical School
Professor of Clinical Immunology and Allergy
University of São Paulo
Development and clinical trial of an attenuated tetravalent dengue vaccine
There are over 300 million cases of dengue worldwide per year. Some are serious and even fatal. The disease burden occurs in tropical and subtropical areas. There is no treatment and the licensed vaccine does not provide the proper protection. NIH, in collaboration with Brazilian institutions, has been developing a tetravalent attenuated dengue vaccine. Brazil is responsible for industrial and clinical development. Currently in phase 3 clinical trial, more than 17,000 volunteers have been recruited. The talk will present the scientific results.
Click here to view the poster for this event